

Ref: GLL/BSE/2025-26/Aug -

Date: August 14, 2025

To
The General Manager,
Corporate Relations Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, **Mumbai - 400001.**
Maharashtra State, India.
Script Code: 531739

To
The Listing Manager,
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex, Opp. Sahajanand
College, 120 Feet Ring Road, Panjara Pol,
Ambawadi, **Ahmedabad - 380015.**
Gujarat State, India.
Script Code:

To
The Calcutta Stock Exchange Limited,
#7, Lyons Range, Murgighata,
Dalhousie, **Kolkata - 700001,**
West Bengal State, India.
Scrip Code: 26178

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting of Gennex Laboratories Limited –
Scrip Code: 531739/GENNEX**

Ref: Regulation 29, 33 & 47 of the SEBI (LODR) 'Regulations, 2015.

In just concluded Meeting of Board of Directors, the Board Approved and considered the following items:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2025 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2025 (annexed here with);
3. Other Business items.

We hereby submit that the Board Meeting had commenced at 4:00 PM and concluded at 4.40 PM.

This intimation is also uploaded on the Company website: www.gennexlab.com

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,
Yours faithfully

For Gennex Laboratories Limited

Dinesh Kumar
Kejriwal
Digitally signed by Dinesh
Kumar Kejriwal
Date: 2025.08.14 16:47:13
+05'30'

Dinesh Kumar Kejriwal

Company Secretary & Compliance Officer

Gennex Laboratories Limited

Office: 'Akash Ganga' 3rd Floor, Plot NO.144, Srinagar colony, Hyderabad-500073, T.S. India | Phone: +91-40-67334400 (30 Lines), Fax: +91-40-67334433
Factory: Sy.No.133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist – 502325, Telangana, India | Tel: +91-08458 279406, Telefax: +91-08454 279516

Info@gennexlab.com, www.gennexlab.com ■ CIN :L L24230TG1990PLC011168

GENNEX LABORATORIES LIMITED

Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal,

Dist : Sangareddy, Telangana - 502 325. INDIA

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN : L24230TG1990PLC011168

Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2025

(Rs. In Lacs)

S No.	PARTICULARS	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)	30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Income								
	Revenue from Operations	2564.00	2328.17	2133.40	9457.79	3417.75	4032.53	2832.18	13790.30
	Other Income	226.44	286.82	245.93	922.13	227.74	383.44	246.50	1043.01
	Total Income	2790.44	2614.99	2379.33	10379.92	3645.49	4415.97	3078.68	14833.31
2	Expenses								
(a)	Cost of material consumed	1826.97	2144.82	1118.87	6718.15	2381.96	3305.55	1802.20	10058.95
(b)	Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(c)	Changes in stock-in-trade and Work in Progress and stock in trade	-98.80	-280.59	213.16	-70.14	-162.26	-76.05	-22.28	-350.58
(d)	Employees Cost	188.03	188.80	190.43	642.50	269.02	207.73	229.22	834.69
(e)	Depreciation	19.87	22.59	17.18	76.95	50.40	54.32	45.30	199.08
(f)	Finance Cost	59.15	53.49	29.49	158.45	97.90	120.00	73.17	360.77
(g)	Other Expenses	310.26	253.22	318.60	1132.85	421.82	393.95	400.22	1575.44
	Total Expenses	2305.49	2382.33	1887.73	8658.76	3058.84	4005.50	2527.83	12678.35
3	Total Profit before exceptional Items & Tax.	484.95	232.67	491.60	1721.15	586.64	410.46	550.84	2154.96
4	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Corporate Social Responsibilites	0.00	-15.00	0.00	15.00	0.00	-15.00	0.00	-15.00
5	Total profit before tax	484.95	217.67	491.60	1706.15	586.64	395.46	550.84	2139.96
6	Tax expense for earlier years	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7	Curent tax	-70.00	-62.00	-75.00	-297.00	-85.00	-83.00	-85.00	-322.00
8	Deferred Tax	0.00	-5.47	0.00	-5.47	0.00	-5.47	0.00	-5.47
9	Total Tax Expenses	-70.00	-67.47	-75.00	-302.47	-85.00	-88.47	-85.00	-327.47
10	Net profit (Loss)	414.95	150.20	416.60	1403.68	501.64	306.99	465.84	1812.49
11	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	-	0.00	0.00	0.00	
12	Total Profit (losss) for period	414.95	150.20	416.60	1403.68	501.64	306.99	465.84	1812.49
13	Other comprehensive income net of taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
14	Total Comprehensive income for the period	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive income for the period attributable to								
	Comprehensive income for the period attributable to owners of parent	0.00	0.00	0.00	0.00	459.16	232.24	441.72	1612.30

	Total comprehensive income for the period attributable to owners of parent non controlling interests	0.00	0.00	0.00	0.00	42.48	74.75	24.12	200.19
16	Details of equity share capital								
	Paid up equity share capital	2314.48	2274.48	2274.48	2274.48	2314.48	2274.48	2274.48	2274.48
	Face value of equity share capital in Rs	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
17	Earnings per share								
	- Basic	0.179	0.066	0.183	0.617	0.217	0.135	0.205	0.793
	- Diluted	0.171	0.065	0.183	0.607	0.206	0.133	0.205	0.784

Notes to the results:

- 1 The above unaudited financial results have been reviewed by the Audit Committee of its meeting held on 14.08.2025 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.
- 2 The Statutory Auditors of the Company have carried out the Limited review of the above unaudited financial results for the Quarter ended June 30, 2025.
- 3 The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (IND-AS) prescribed u/s 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 4 The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Primary segment and believes that the Company has only one reportable segment namely "Bulk Drugs,Biotech Products and Intermediates".Previous period's figures have been rearranged/regrouped wherever necessary.
- 5 Adjustment of actuarial valuation in respect of compliance with Accounting Standard- IAS-19-'Employee Benefits' is to be done at the year end.
- 6 Quarter ended 30th June,2025 Consolidated figures includes Sales (Net) of Rs.322.93 Lacs & Purchase(Net) of Rs 0.156 lacs to subsidiary "Deccan Remedies Ltd".
- 7 The quarterly unaudited financial results for the Quarter ended June 30, 2025 are available on the Company's Website i.e;www.gennexlab.com and also available on BSE website i.e; www.bseindia.com.

**For and on behalf of the Board
For Gennex Laboratories Limited**

ARIHANT
BAID

Digitally signed by
ARIHANT BAID
Date: 2025.08.14 16:51:28
+05'30'

**Arihant Baid
Managing Director**

Place: Hyderabad
Date: 14.08.2025

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Standalone financial results for quarter ended 30th June, 2025 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Gennex Laboratories Limited** for the Quarter ended June 30, 2025 and for the period from April 01, 2025 to June 30, 2025 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliances with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention, except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R PUGALIA & COMPANY

Chartered Accountants

Firm Registration No.318188E


RAJEEV KUMAR PUGALIA

Membership No.053972

Place: Kolkata

Date: 14th August 2025

UDIN: 25053972BMMKGM8171

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Consolidated financial results for quarter ended 30th June, 2025 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s. Gennex Laboratories Limited** ("the Company") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its Subsidiary for the quarter ended June 30, 2025, and for the period from April 01, 2025 to June 30, 2025 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures corresponding quarter ended June 30, 2025 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of Deccan Remedies Limited. (Subsidiary Company)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Subsidiary, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 855.05 Lakhs, total net Profit after tax of Rs. 86.69 Lakhs for the quarter ended June 30, 2025 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of this Subsidiary, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For R PUGALIA & COMPANY

Chartered Accountants

Firm Registration No. 118188E




RAJEEV KUMAR PUGALIA

Membership No.053972

Place: Kolkata

Date: 14th August 2025

UDIN: 25053972BMMKGL1712